Dr. Michael S. Chapman, M.D.
Dermatology (Dermatology Physician)
18 Old Etna Rd, Dh - Dermatology
Lebanon, NH 03766
Who else practices at this address →
Grafton County includes mental health (62% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- University of Texas Medical School at Houston (1995)
- Years since graduation
- 31
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 449
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1995Medical school: University of Texas Medical School at Houston
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Dermatology Physician primary
NH license 10606
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Mary Hitchcock Memorial Hospital Lebanon, NH
Medical groups
- Dartmouth-Hitchcock Clinic (1,472 clinicians)
- Mary Hitchcock Memorial Hospital (1,280 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 449
- Services billed
- 2,462
- Patients’ average age
- 77
| Service | Times | Patients |
|---|---|---|
| Destruction of precancer skin growth, 2-14 growths | 941 | 201 |
| Established patient office or other outpatient visit, 20-29 minutes | 425 | 337 |
| Destruction of precancer skin growth, 1 growth | 326 | 242 |
| Destruction of skin growth, 1-14 growths | 204 | 177 |
| Established patient office or other outpatient visit, 30-39 minutes | 137 | 119 |
| Established patient office or other outpatient visit, 10-19 minutes | 97 | 88 |
| Biopsy of related skin growth, first growth | 55 | 54 |
| Destruction of cancer skin growth of trunk, arms, or legs, 0.6-1.0 cm | 29 | 25 |
| Destruction of cancer skin growth of trunk, arms, or legs, 0.5 cm or less | 25 | 18 |
| New patient office or other outpatient visit, 30-44 minutes | 19 | 19 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Triamcinolone Acetonide Other prescribers in Lebanon, NH | 77 |
| Otezla (apremilast) Other prescribers in Lebanon, NH | 58 |
| Minoxidil Other prescribers in Lebanon, NH | 48 |
| Mycophenolate Mofetil Other prescribers in Lebanon, NH | 40 |
| Prednisone Other prescribers in Lebanon, NH | 38 |
| Clobetasol Propionate Other prescribers in Lebanon, NH | 37 |
| Doxycycline Hyclate Other prescribers in Lebanon, NH | 37 |
| Tacrolimus Other prescribers in Lebanon, NH | 37 |
| Econazole Nitrate | 30 |
| Fluorouracil Other prescribers in Lebanon, NH | 29 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 2 companies reported 4 payments worth $3,030 in total to this clinician.
| Biofrontera Inc. | $2,947 |
|---|---|
| Janssen Biotech, Inc. | $82.95 |
| Consulting Fee | $2,750 |
|---|---|
| Food and Beverage | $197 |
| Education | $82.95 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Biofrontera Inc. Jul 25, 2025 | Consulting Fee | $2,750 |
| Janssen Biotech, Inc. Apr 16, 2025 | Education TREMFYA · Immunology · in-kind | $82.95 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $16,102 in research payments for these studies, mostly to the institutions running them.
- Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Superficial Basal Cell Carcinoma (sBCC) With Photodynamic Therapy (PDT).
Biofrontera Inc. · Active, not recruiting · NCT03573401
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.